Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

Clinical Gastroenterology and Hepatology

Volumn 13, Issue 6, 2015, Pages 1103-1110

  Papamichael, Konstantinos ^a,b,c   Vande Casteele, Niels ^b   Gils, Ann ^b   Tops, Sophie ^b   Hauenstein, Scott ^d   Singh, Sharat ^d   Princen, Fred ^d   Van Assche, Gert ^a,c   Rutgeerts, Paul ^a,c   Vermeire, Severine ^a,c   Ferrante, Marc ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d HP Incorporated   (United States)

Author keywords

Anti TNF Agent; Anti Tumor Necrosis Factor; Inflammatory Bowel Disease; Prognosis; Serology; VCAM

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; VASCULAR CELL ADHESION MOLECULE 1; AUTACOID; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; BELGIUM; BLOOD SAMPLING; COHORT ANALYSIS; CROHN DISEASE; DISEASE DURATION; DRUG WITHDRAWAL; ENDOSCOPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; REMISSION; RETROSPECTIVE STUDY; ADOLESCENT; BLOOD; CHEMISTRY; MIDDLE AGED; PATHOLOGY; SERUM; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; YOUNG ADULT;

ADOLESCENT; ADULT; BELGIUM; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; INFLIXIMAB; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SERUM; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84930377782     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2014.11.026     Document Type: Article

References (27)

1. Billiet T., Rutgeerts P., Ferrante M., et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther 2014, 14:75-101.
2. Choi G.K., Collins S.D., Greer D.P., et al. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease. JCrohns Colitis 2013, 8:375-383.
3. Siegel C.A., Marden S.M., Persing S.M., et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
4. D'Haens G.R., Panaccione R., Higgins P.D., et al. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199-212.
5. Krupa L.Z., Kennedy H.J., Jamieson C.P., et al. The reasons for discontinuation of infliximab treatment in patients with Crohn's disease: a review of practice at NHS teaching hospital ISRN. Gastroenterology 2011, 672017:1-3.
6. Molander P., Färkkilä M., Salminen K., et al. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission. Inflamm Bowel Dis 2014, 20:1021-1028.
7. Louis E., Mary J.Y., Vernier-Massouille G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
8. Waugh A.W., Garg S., Matic K., et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010, 32:1129-1134.
9. Molnar T., Farkas K., Miheller P., et al. Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?. JCrohns Colitis 2008, 2:322-326.
10. Molnar T., Lakatos P.L., Farkas K., et al. Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy. Aliment Pharmacol Ther 2013, 37:225-233.
11. Domenech E., Hinojosa J., Nos P., et al. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated?. Aliment Pharmacol Ther 2005, 22:1107-1113.
12. Steenholdt C., Molazahi A., Ainsworth M.A., et al. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012, 47:518-527.
13. Lu C., Waugh A., Bailey R.J., et al. Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol 2012, 18:5058-5064.
14. Farkas K., Lakatos P.L., Nagy F., et al. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy. Scand J Gastroenterol 2013, 48:1394-1398.
15. Kamm M.A., Ng S.C., De Cruz P., et al. Practical application of anti-TNF therapy for luminal Crohn's disease. Inflamm Bowel Dis 2011, 17:2366-2391.
16. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
17. Vande Casteele N., Buurman D.J., Sturkenboom M.G., et al. Detection of infliximab concentrations and anti-infliximab antibodies: a comparison of three different assays. Aliment Pharmacol Ther 2012, 36:765-771.
18. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. NEngl J Med 2003, 348:601-608.
19. Landers C.J., Cohavy O., Misra R., et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology 2002, 123:689-699.
20. Clarke K., Regueiro M. Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2012, 18:174-179.
21. Peyrin-Biroulet L., Danese S. Stopping infliximab in Crohn's disease: still an ongoing STORI. Inflamm Bowel Dis 2012, 18:2201-2202.
22. Sorrentino D., Nash P., Viladomiu M., et al. Stopping anti-TNF agents in patients with Crohn's disease in remission: is it a feasible long-term strategy?. Inflamm Bowel Dis 2014, 20:757-766.
23. Gearry R.B., Kamm M.A., Hart A.L., et al. Predictors for developingintestinal failure in patients with Crohn's disease. JGastroenterol Hepatol 2013, 28:801-807.
24. Ferrante M., Henckaerts L., Joossens M., et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007, 56:1394-1403.
25. Panes J., Granger D.N. Leukocyte-endothelial cell interactions: molecular mechanisms and implications in gastrointestinal disease. Gastroenterology 1998, 114:1066-1090.
26. Wellicome S.M., Kapahi P., Mason J.C., et al. Detection of a circulating form of vascular cell adhesion molecule-I: paired concentrations in rheumatoid arthritis and systemic lupus erythematosus. Clin Exp Immunol 1993, 92:412-418.
27. Chidlow J.H., Shukla D., Grisham M.B., et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol 2007, 293:G5-G18.